MAINZ / LONDON (IT BOLTWISE) – BioNTech has made significant progress in its oncology strategy by focusing on cross-tumor programs and innovative combination therapies. The company plans to increase its financial guidance for 2025 as it continues to invest in developing new cancer treatments. The collaboration with Bristol Myers Squibb is already showing promising results, particularly in the development of the antibody Pumitamig.
Today’s daily deals at Amazon! ˗ˋˏ$ˎˊ˗
BioNTech, a leader in immunotherapy, made significant progress in its oncology strategy in the third quarter of 2025. The company focuses on two cross-tumor programs and innovative combination therapies to cover the entire spectrum of cancer diseases. Of particular note is the development of the bispecific antibody Pumitamig, which is being developed in collaboration with Bristol Myers Squibb. Initial interim results from a global phase 2 study show encouraging anti-tumor activity in advanced small cell lung cancer.
BioNTech raised its financial forecasts for the 2025 financial year. The company now expects sales of between 2.6 and 2.8 billion euros, while research and development expenses have been reduced to 2.0 to 2.2 billion euros. These adjustments reflect the strategic direction aimed at sustainable development and operational efficiency. Receiving $1.5 billion from the partnership with Bristol Myers Squibb underscores the strategic value of this collaboration.
BioNTech has also launched a variant-adapted COVID-19 vaccine for the 2025/2026 vaccination season. This move demonstrates the company’s commitment to responding to current healthcare needs while continuing to expand its oncology pipeline. The clinical development of Pumitamig continues in several pivotal studies to provide new therapeutic options for patients with cancer.
The collaboration with Bristol Myers Squibb is a key part of BioNTech’s strategy to develop transformative therapeutic options for cancer patients. The planned studies for Pumitamig as a first-line therapy for microsatellite-stable colorectal cancer and gastric cancer demonstrate the company’s commitment to advancing innovative solutions in the field of oncology. These developments could significantly improve treatment options for cancer patients worldwide.
Order an Amazon credit card without an annual fee with a credit limit of 2,000 euros!
Bestseller No. 1 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 2 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 3 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 4 ᵃ⤻ᶻ «KI Gadgets»
Bestseller No. 5 ᵃ⤻ᶻ “KI Gadgets”
Please send any additions and information to the editorial team by email to de-info[at]it-boltwise.de. Since we cannot rule out AI hallucinations, which rarely occur with AI-generated news and content, we ask you to contact us via email and inform us in the event of false statements or misinformation. Please don’t forget to include the article headline in the email: “BioNTech’s advances in oncology and financial forecasts for 2025”.